CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy

BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard therapeutic strategy for triple-negative breast cancer (TNBC). TNBC patients with residual disease after NAC have a significantly worse survival than those with pathological complete response (pCR); however, there is no apparent prognostic f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokunaga, Eriko, Fujita, Aya, Takizawa, Katsumi, Baba, Kimiko, Akiyoshi, Sayuri, Nakamura, Yoshiaki, Ijichi, Hideki, Masuda, Takanobu, Koga, Chinami, Tajiri, Wakako, Ohno, Shinji, Taguchi, Kenichi, Ishida, Mayumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314992/
https://www.ncbi.nlm.nih.gov/pubmed/29971631
http://dx.doi.org/10.1007/s12282-018-0888-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314992/
https://www.ncbi.nlm.nih.gov/pubmed/29971631
http://dx.doi.org/10.1007/s12282-018-0888-y

Ejemplares similares